The specifics, since they change the answer: vomiting · retatrutide · TRIUMPH-3.
I have the document in front of me and I can read the numbers. What I cannot do is interpret them.
I am reasonably comfortable with statistics and completely uncomfortable with chromatography, or vice versa.
What does this actually establish, and what does it not?
Take it from the TRIUMPH-3 adverse-event table by arm, and check the unit before you use it. An incidence can be the proportion of participants who reported the event at least once, or the count of events divided by exposure time, and the two differ by however many people had it repeatedly. Then subtract the placebo arm, because the untreated rate is not zero. And read the discontinuation column beside it: an event that made people leave the trial is under-counted at every later visit, so a low late-timepoint incidence can mean the event was severe rather than rare.
Worth being precise here: rehydration with an oral rehydration solution is more effective than water and is not the same as a sports drink.
Oral rehydration solutions work by glucose-coupled sodium co-transport, which continues to function when secretion is deranged. That is why the glucose-to-sodium ratio matters and a high-sugar sports drink is not equivalent.
Repeated vomiting is the mechanism behind most reported acute kidney injury in this class. The renal event is a volume event, not a direct toxicity.
Vomiting rates in the trial programmes are reported separately from nausea and are consistently lower and more dose-dependent.
Anti-emetics interact with other medication and are a prescriber decision.
Small frequent sips of an oral rehydration solution, not large volumes of water.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsOn the detail: anti-emetics are a clinical decision and not a self-management step.
Trial incidence for vomiting runs at roughly a third to a half of the nausea rate depending on agent and dose, and it is more concentrated in the escalation phase than nausea is.
Warning signs that convert this from a nuisance to a clinical problem: inability to keep fluids down for more than a few hours, reduced urine output, dizziness on standing, confusion, or severe abdominal pain.
Nothing here is medical advice.
Do not escalate the dose while this is happening.
edited 10 May 2024 by jo_vandeberg — added the method parameters
Answer first: vomiting is less common than nausea, is more strongly dose-related, and matters chiefly because of what it does to fluid and electrolyte balance.
An episode of vomiting several days after a dose, with no escalation and no other explanation, is not the typical pattern and deserves attention rather than tolerance.
In practice, dental enamel erosion from repeated vomiting is a real if unglamorous consequence; rinsing with water rather than brushing immediately is the standard advice.
Oral rehydration solution composition is standardised by the World Health Organization and rests on glucose-coupled sodium transport.
Rinse rather than brush after an episode. Enamel is not replaceable.
Start with frequency and duration, because an isolated episode after an escalation and repeated episodes over days are different problems.
Fluid lost in vomit carries sodium at roughly 60 millimoles per litre and potassium at rather less, so replacing it with plain water alone dilutes plasma sodium rather than restoring balance.
Volume depletion as the mechanism for acute creatinine rise is basic renal physiology and explains the pattern of renal reports in this class.
The caveat is that persistent vomiting is a clinical situation and this is not the place to manage one.
If fluids will not stay down for several hours, that is the threshold. Get help.
The short version: usually escalation-related, usually self-limiting, and dangerous mainly through dehydration.
A practical home formulation is about six level teaspoons of sugar and half a level teaspoon of salt in one litre of water, taken in small frequent sips rather than in volumes that provoke another episode.
Research-use material is not approved for human use, and an unverified dose is an unquantifiable variable in any of this.
The renal risk here is volume, not toxicity. That is the mechanism to watch.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.